Litcius/Paper detail

879P VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)

Jessica Weiss, John M. Kaczmar, Kevin J. Harrington, Rukmankesh Mehra, Frank Worden, R. Zinner, Anil K. Giri, Hyunseok Kang, Sidra Najeeb, Timothy Panella, Ammar Sukari, Clíona Grant, V.P. Kaur, Simon W. Jones, David Schaaf, Katharine A. Price

2024Annals of Oncology11 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePembrolizumabHead and neck squamous-cell carcinomaOncologyInternal medicineHead and neckHead and neck cancerImmunotherapyCancer researchCancerSurgeryCancer Immunotherapy and BiomarkersHead and Neck Cancer StudiesCancer Diagnosis and Treatment
879P VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) | Litcius